Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections

Not Applicable

• Conditions: Surgical Wound Infection; Cesarean Section; Staphylococcus Aureus
• Interventions: Drug: Mupirocin

• Registration Number: NCT01152593
• Lead Sponsor: Hillel Yaffe Medical Center

Brief Summary

The investigators believe that irradication of nose colonization of staphyloccocus aureus will reduce the incidence of surgical site infections after cesarean section.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-05-31
• Status Verified: 2010-06
• Study First Submitted QC: 2010-06-28
• Last Update Submitted: 2010-06-28
• Study First Posted: 2010-06-29
• Last Update Posted: 2010-06-29
• Study Start: 2010-07
• Primary Completion: 2014-07
• Study Completion: 2014-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 400

Inclusion Criteria

• Women assigned to undergo cesarean section

Exclusion Criteria

• All others

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Intranasal Mupirocin	Mupirocin	-

Primary Outcome Measures

Name	Time	Method
Reduction of the incidence of surgical site infections after cesarean section	Four years

Trial Locations

Locations (1)

Hillel Yaffe Medical Center; 🇮🇱 Hadera, Israel